MARLBOROUGH, Mass., Jan. 14, 2021 /PRNewswire/ -- Boston Scientific (NYSE: BSX) has announced a limited market release of the WaveWriter Alpha™ portfolio of Spinal Cord Stimulator (SCS) systems. The ...

Just as a rising tide is said to lift all boats, so too is a new FDA clearance expanding the reach of all of Boston Scientific’s WaveWriter spinal cord stimulation systems. The devices—which include ...

Boston Scientific, Inc. BSX recently received FDA approval for an expanded indication of the WaveWriter Alpha Spinal Cord Stimulator (“SCS”) Systems. With this approval, the system will be available ...

Boston Scientific has won approval for its Wavewriter spinal cord stimulator (SCS) systems in non-surgical back pain (NSBP). The U.S. Food and Drug Administration approval expands the label of the ...

Boston Scientific is hopping on the bandwagon as the latest developer of a spinal cord stimulation system to receive FDA approval for diabetic neuropathy pain relief. The newly handed-down regulatory ...

Marlborough medical device manufacturer Boston Scientific Corp. has announced a limited market release of a new pain-relief system that uses electrical impulses in the spine to block pain signals. The ...

Marlborough medical technology firm Boston Scientific has received approval from the U.S. Food and Drug Administration for its WaveWriter Alpha spinal cord stimulator device to be used to treat low ...

(RTTNews) - Boston Scientific (BSX) announced Thursday a limited market release of the WaveWriter Alpha portfolio of Spinal Cord Stimulator (SCS) systems. This is an unified portfolio of four MRI ...